Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review
Abstract Background Squamous cell carcinoma (SCC) is a relatively common and heterogenous malignancy of different organs, such as the skin, esophagus, and lungs. Although most cases experience good survival with surgical methods, management of advanced types of the disease remains challenging. Sever...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1802 |
| _version_ | 1827950181468864512 |
|---|---|
| author | Amirhossein Tamimi Atena Tamimi Fatemeh Sorkheh Saba Mardekatani Asl Arezoo Ghafari Arian Ghannadi Karimi Gisou Erabi Hossein Pourmontaseri Niloofar Deravi |
| author_facet | Amirhossein Tamimi Atena Tamimi Fatemeh Sorkheh Saba Mardekatani Asl Arezoo Ghafari Arian Ghannadi Karimi Gisou Erabi Hossein Pourmontaseri Niloofar Deravi |
| author_sort | Amirhossein Tamimi |
| collection | DOAJ |
| description | Abstract Background Squamous cell carcinoma (SCC) is a relatively common and heterogenous malignancy of different organs, such as the skin, esophagus, and lungs. Although most cases experience good survival with surgical methods, management of advanced types of the disease remains challenging. Several modalities, including different chemotherapy regimens and immunotherapies, have been investigated in this matter, among which Monoclonal antibodies (Mabs) are one of the most promising ones. Since the development of Mabs, they have been widely used to treat different diseases. Mabs have shown significant efficacy with high specificity along with acceptable safety, which makes them a favorable option in cancer therapy. In this article, we aimed to review the different aspects of using Mabs in SCC therapy. Recent Findings We found that treating with different Mabs has shown excellent efficacy accompanied by acceptable safety in treating SCC of different organs. Therefore, Mabs are considered great options in the treatment of SCC, especially in advanced cases. Overall, two highly potent types of Mabs in SCC therapy are anti‐EGFR Mabs and checkpoint inhibitors, especially Cetuximab, Nimotuzumab, and PD‐1 inhibitors. Bevacizumab is also a promising option as adjuvant therapy to other modalities. Conclusion Although some Mabs have shown promising outcomes in SCC therapy, their application as a part of cancer treatment depends on further investigations regarding cost‐effectiveness and predictors of response. FDA has approved several Mabs in SCC therapies, and Mabs may have a crucial role in this era in the near future, especially in treating head and neck and esophageal SCC and metastatic lung cancer. |
| first_indexed | 2024-04-09T13:22:33Z |
| format | Article |
| id | doaj.art-3243eef9026b4c1faa067a98af448e2b |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-04-09T13:22:33Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-3243eef9026b4c1faa067a98af448e2b2023-05-11T02:44:36ZengWileyCancer Reports2573-83482023-05-0165n/an/a10.1002/cnr2.1802Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature reviewAmirhossein Tamimi0Atena Tamimi1Fatemeh Sorkheh2Saba Mardekatani Asl3Arezoo Ghafari4Arian Ghannadi Karimi5Gisou Erabi6Hossein Pourmontaseri7Niloofar Deravi8Student Research Committee, School of Medicine Guilan University of Medical Sciences Rasht IranStudent Research Committee, School of Medicine Shahid Beheshti University of Medical Sciences Tehran IranStudent Research Committee Babol University of Medical Sciences Babol IranStudent Research Committee, School of Medicine Shahid Beheshti University of Medical Sciences Tehran IranStudent Research Committee, School of Medicine Shahid Beheshti University of Medical Sciences Tehran IranStudent Research Committee Qazvin University of Medical Science Qazvin IranStudent Research Committee Urmia University of Medical Sciences Urmia IranStudent Research Committee Fasa University of Medical Sciences Fasa IranStudent Research Committee, School of Medicine Shahid Beheshti University of Medical Sciences Tehran IranAbstract Background Squamous cell carcinoma (SCC) is a relatively common and heterogenous malignancy of different organs, such as the skin, esophagus, and lungs. Although most cases experience good survival with surgical methods, management of advanced types of the disease remains challenging. Several modalities, including different chemotherapy regimens and immunotherapies, have been investigated in this matter, among which Monoclonal antibodies (Mabs) are one of the most promising ones. Since the development of Mabs, they have been widely used to treat different diseases. Mabs have shown significant efficacy with high specificity along with acceptable safety, which makes them a favorable option in cancer therapy. In this article, we aimed to review the different aspects of using Mabs in SCC therapy. Recent Findings We found that treating with different Mabs has shown excellent efficacy accompanied by acceptable safety in treating SCC of different organs. Therefore, Mabs are considered great options in the treatment of SCC, especially in advanced cases. Overall, two highly potent types of Mabs in SCC therapy are anti‐EGFR Mabs and checkpoint inhibitors, especially Cetuximab, Nimotuzumab, and PD‐1 inhibitors. Bevacizumab is also a promising option as adjuvant therapy to other modalities. Conclusion Although some Mabs have shown promising outcomes in SCC therapy, their application as a part of cancer treatment depends on further investigations regarding cost‐effectiveness and predictors of response. FDA has approved several Mabs in SCC therapies, and Mabs may have a crucial role in this era in the near future, especially in treating head and neck and esophageal SCC and metastatic lung cancer.https://doi.org/10.1002/cnr2.1802anti‐cancerimmunotherapymonoclonal antibodysquamous cell carcinoma |
| spellingShingle | Amirhossein Tamimi Atena Tamimi Fatemeh Sorkheh Saba Mardekatani Asl Arezoo Ghafari Arian Ghannadi Karimi Gisou Erabi Hossein Pourmontaseri Niloofar Deravi Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review Cancer Reports anti‐cancer immunotherapy monoclonal antibody squamous cell carcinoma |
| title | Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review |
| title_full | Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review |
| title_fullStr | Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review |
| title_full_unstemmed | Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review |
| title_short | Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review |
| title_sort | monoclonal antibodies for the treatment of squamous cell carcinoma a literature review |
| topic | anti‐cancer immunotherapy monoclonal antibody squamous cell carcinoma |
| url | https://doi.org/10.1002/cnr2.1802 |
| work_keys_str_mv | AT amirhosseintamimi monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview AT atenatamimi monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview AT fatemehsorkheh monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview AT sabamardekataniasl monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview AT arezooghafari monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview AT arianghannadikarimi monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview AT gisouerabi monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview AT hosseinpourmontaseri monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview AT niloofarderavi monoclonalantibodiesforthetreatmentofsquamouscellcarcinomaaliteraturereview |